No differences were revealed in the frequencies of the CYP2B6 variant genotypes between patients and healthy donors according to age, suggesting that the CYP2B6 polymorphism does not modulate AML risk in an age-dependent manner. This evidence concerns the gene CYP2B6 and acute myeloid leukemia.